GENFIT: NIS2+® Included in New Clinical Guidelines for MASLD

GENFIT, a late-stage biopharmaceutical company, announced the inclusion of its NIS2+® technology as a key tool in the latest European Clinical Practice Guidelines for managing metabolic dysfunction-associated steatotic liver disease (MASLD). The guidelines were developed by the European associations for the study of liver, diabetes, and obesity. They provide updates on prevention, screening, diagnosis, and treatment of MASLD.

Dean Hum, Chief Scientific Officer at GENFIT, stated that this inclusion is a significant recognition based on solid evidence that NIS2+® could help identify patients who may benefit from new treatments for metabolic dysfunction-associated steatohepatitis (MASH).

NIS2+® is now featured as a non-invasive method for detecting at-risk MASH, the only blood-based test mentioned for this condition. With the recent FDA approval of resmetirom and the limitations of liver biopsy in clinical practice, non-invasive panels like NIS2+® could help in selecting patients for pharmacotherapy.